Why the study?
Does fibrate treatment compared to statin treatment affect carotid intima-media thickness and arterial remodeling in dyslipidemic subjects?
Does fibrate treatment compared to statin treatment affect carotid intima-media thickness and arterial remodeling in dyslipidemic subjects?
Fibrate treatment is associated with greater carotid intima-media thickness and less compensatory carotid enlargement compared to statin treatment in dyslipidemic patients, independent of LDL cholesterol levels.
Answers are grounded in this paper and cite their sources.
Fibrate-associated greater IMT versus statins in this cohort should not yet change practice; leaves open need for randomized outcome trials.
BACKGROUND: The effects of statins on intima-media thickness (IMT) are well documented, whereas those of fibrates are unknown. Therefore we compared IMT under treatment with each class of drugs. METHODS: We studied a cohort of consecutive dyslipidemic subjects treated with statin (n = 291) or fibrate (n = 82) drugs. Fibrate-treated subjects were matched with the same number of statin-treated subjects to obtain two subgroups of similar demographic and risk factors including LDL cholesterol. Common carotid far wall IMT and lumen diameter were measured by ultrasonography. RESULTS: In the entire study population, IMT was greater in the fibrate group than in the statin group (P < .001), even after adjustment for LDL cholesterol and other covariates (P < .05). In the matched groups, IMT was greater in fibrate group than in the statin group (P < .01), even after adjustment for LDL cholesterol and other covariates including treatment duration (P < .01). The IMT correlated positively with treatment duration in the fibrate group (P < 0.05) but not in the statin group. In addition, IMT correlated positively with carotid lumen diameter in both the fibrate and statin groups (P < .05, P < .01) but with a lower slope in the former (P < .05). CONCLUSIONS: In this study fibrate treatment was associated with greater IMT, steeper IMT-time relationship, and lower compensatory carotid enlargement than was statin treatment. These differences were not explained by differences in LDL cholesterol.
No takes yet. Share an insight, caveat, or question.
Chironi et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: